BTK and B-cell chronic lymphocytic leukemia: Our findings indicate that BTK inhibitors, such as ibrutinib or zanubrutinib, fail to inhibit Wnt5a-induced NF-κB activation or expression of MMP-9, suggesting a potential mechanism for drug resistance and disease progression in CLL.